Catalytic immune adjuncts crack mucosa immune bottlenecks

, the mucous membrane immune system is the largest immune system in the host body. Its powerful mucous membrane defense system also hinders antigen delivery and immune response activation of mucous membrane vaccine, which has been a difficult point in the development of mucosal vaccine. Recently, Advanced Science published online a new mucous membrane immunodiodesic agent developed in collaboration with Yangzhou University and the Institute of Biophysics of the Chinese Academy of Sciences, cracking the key bottleneck of mucosal vaccine.
Daxin, a professor at Yangzhou University's School of Veterinary Medicine, said the mucous membrane is the gateway for the vast majority of pathogenic microorganisms to invade the host, and the mucous membrane immune system distributed in it has more than 50% of the host's lymphatic tissue and 80% of the immune cells. The mucous membrane immune system is widely distributed in the respiratory, digestive and reproductive tract mucous membranes, with dense mucosa barrier system, rich immune cells, forming the first line of defense against pathogenic microorganisms.
If potential mucous membrane vaccines can be developed, a solid "great wall" will be built at the boundaries of the host defense, and the level of mucosal immune response will be strengthened, which will help effectively cut off further infection and spread of pathogens at an early stage.
Peng Daxin said that influenza is very important human and animal diseases. Although needle injection vaccine research and development and application has been more common, can effectively activate the host's systemic immune response, can greatly enhance the level of circulatory antibodies throughout the body, however, it is often difficult to effectively induce mucosa immune response, blocking influenza virus infection and detoxification at the mucous membrane. Therefore, it is necessary to study and apply an efficient influenza mucosa vaccine.
, efficient and low-cost immunodrage is an important strategy to solve the bottleneck of influenza mucosa vaccine. Peng Daxin led the team based on the basis of pre-nanoenzyme research, the development of new ad adhesives.
Tao, a veterinary college at Yangzhou University, told reporters that the new adjulytics enhance the delivery of influenza antigens through a dual mechanism. On the one hand, by optimizing the positive charge distribution ratio of the surface of the preparation, the target delivery efficiency of the mucous membrane of influenza antigen is significantly improved; Road, significantly promote the secretion of the coercion factor CCL20, mobilize antigen-dendrites cells to collect to the mucous membrane area, and actively open the mucosa epithal cell connection, outstretched across the epithal dendrites, ingestion of intra-cavity influenza antigens.After the
influenza antigen and adjunct were successfully captured by the dexterous cells, the adjunct was able to play the activity of peroxidase, significantly increase the reactive oxygen level and promote its mature differentiation through the enzyme catalytic reaction, and further activate a series of natural immune responses downstream, enhance the antigen delivery ability, and ultimately induce high levels of sIgA mucosal immune response.
The research results for the first time put forward the concept of 'catalytic immune adjunct', the design of influenza nasal vaccine with multi-cell targeting ability, can break through the mucous membrane barrier to achieve efficient delivery of influenza antigens, induce a high level of mucosal immune response, for the influenza mucosa vaccine design provides a new idea. (Source: Li Chen Sha Aihong, China Science Journal)
related paper information: